China's Rheumatoid Arthritis Drug Market Will More than Double by 2013

Western Branded Drug Sales Will Command 54 Percent of the Market by 2013,
According to a Report from Decision Resources

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms focusing on pharmaceutical and healthcare
issues, finds that the rheumatoid arthritis (RA) drug market will more than
double by 2013, growing from $138 million in 2008 to $385 million in 2013.
This growth will be fueled by a growing drug-treated population, increasing
patient access to healthcare insurance, greater patient spending power and
increased use of biological agents in RA treatment.

"A principal driver of growth in the Chinese RA market is the expanding
patient population. We expect the number of patients eligible for drug therapy
to increase 52 percent by 2013. During the same 2008-2013 time period, the
drug-treated population will grow approximately 80 percent," stated Jing Wu,
M.S., MBA.

The new Emerging Markets report entitled Rheumatoid Arthritis in China also
finds that Western branded drug sales will command 54 percent of the market by
2013. The key drivers of this growth will be the increased uptake of currently
available Western branded biologics and the launch of new biologics. The best
opportunities for Western drug companies are in the launch and marketing of
new biological agents that are easily administered and have novel mechanisms
of action that achieve quicker onset of disease-modifying activity.

"We expect less competition from Chinese generic versions of new Western
branded biologics than for small-molecule drugs for two reasons: biologics are
harder to imitate than small chemical molecules and it is difficult to
convince physicians that biosimilars have the same activity as the original
brands," added Ms. Wu.

The report contains primary research of physicians and epidemiology study in
key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in
the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and
Jinan.

About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report
series for high-growth emerging markets with comprehensive disease-specific
analysis. Each report assesses the commercial opportunity in the
pharmaceutical market for a disease based on population demographics, economic
development, disease epidemiology and changing physicians' practices.

About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:
Gisselle Morales Elizabeth Marshall
Decision Resources Decision Resources, Inc.
781-296-2691 781-296-2563
gmorales@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Gisselle Morales, Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com